Grove’s technology was invented by the collaborative efforts of Founders Robert Peura, Ph D and Hannu Harjunmaa, Ph D. The seminal invention is the “Optical Bridge,” an optical analogue of the Wheatstone electrical bridge, that enables Grove technology to null the background tissue and its water content, and to sense glucose content in the vascular space.
Protected by 8 issued US and international patents, 1 patent pending, 2 new applications, and several new provisional filings, Grove is the technology leader in noninvasive glucose monitoring. Endorsed by the NIH NIDDK with 10 funded SBIR grants, expert reviewers have repeatedly named Grove the leader both technologically and in clinical results.
The NIH NIDDK has on ten occasions endorsed Grove technology and funded SBIR Grants. Below are some recent quotes from the grant critiques:
- 2008 National Institute of Health, NIDDK
This technology is the most exciting NIR non-invasive glucose measurement system under development.
In 2011, Grove was the recipient of an Accelerator Award from the Massachusetts Life Sciences Center – one of only four awardees out of more than forty Boston area life sciences companies competing.
Grove is moving forward with its first product, a personal glucose meter for use by individuals in the lifelong management of diabetes. Grove’s pipeline also includes a professional glucometer for use by providers on other subjects and a continuous monitor which can serve many market segments including the “artificial pancreas.”
It is also important to note that Grove’s technology is a platform: the technology has already proven that it can “see” other analytes in addition to glucose.